International Urology and Nephrology

, Volume 48, Issue 10, pp 1609–1616 | Cite as

Safety, efficacy and predictors of local recurrence after percutaneous radiofrequency ablation of biopsy-proven renal cell carcinoma

  • Michael Z. Su
  • Fatima Memon
  • Howard M. Lau
  • Andrew J. Brooks
  • Manish I. Patel
  • Henry H. Woo
  • Simon V. Bariol
  • Philip Vladica
Urology - Original Paper



To evaluate the safety and efficacy of percutaneous radiofrequency ablation (RFA) for localised renal cell carcinoma (RCC) and examine potential associations between age, gender, tumour size, location, chronic kidney disease, comorbidities, learning curve and local recurrence.


We retrospectively analysed survival outcomes for patients with biopsy-proven RCC treated by RFA at Westmead Hospital. Complication data were gathered from all patients that underwent renal RFA. 3 and 5 year local recurrence-free (RFS), disease-free (DFS) and overall survival (OS) outcomes were reported. Univariate and multivariate analysis was used to examine each potential predictor.


A total of 168 patients were eligible for the study. Forty-eight patients with biopsy-proven RCC had minimum 3-year follow-up. Our complication rate was 1.2 % (2/168) and local recurrence rate 10.4 % (5/48). Five-year RFS, DFS and OS were 86.8, 82.3 and 92.6 % on a median 4.1-year follow-up (IQR 3.4–4.9). None of the patient or tumour-specific characteristics were associated with RFS.


Radiofrequency ablation performed at our centre was a safe and effective procedure with low complication rates and durable RFS. Tumour characteristics, comorbidities and learning curve were not associated with local recurrence.


Percutaneous ablation Radiofrequency ablation Carcinoma, renal cell Neoplasm recurrence, local Oncological outcomes 



We thank Ms. Pamela Dougan for her invaluable efforts as data administrator, Ms. Karen Byth for her assistance with statistical analysis and Dr. Philip Vladica for acting as the guarantor for this paper.

Compliance with ethical standards

Conflict of interest

Michael Su, Fatima Memon, Howard Lau, Andrew Brooks, Manish Patel, Henry Woo, Simon Bariol and Philip Vladica declares that they have no conflict of interest.


This study did not receive any funding.

Ethical approval

All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional human research ethics committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Choueiri TK, Schutz FAB, Hevelone ND, Nguyen PL, Lipsitz SR, Williams SB, Silverman SG, Hu JC (2011) Thermal ablation vs surgery for localized kidney cancer: a surveillance, epidemiology, and end results (SEER) database analysis. Urology 78:93–98CrossRefPubMedGoogle Scholar
  2. 2.
    Olweny EO, Park SK, Tan YK, Best SL, Trimmer C, Cadeddu JA (2012) Radiofrequency ablation versus partial nephrectomy in patients with solitary clinical T1a renal cell carcinoma: comparable oncologic outcomes at a minimum of 5 years of follow-up. Eur Urol 61:1156–1161CrossRefPubMedGoogle Scholar
  3. 3.
    Tracy CR, Raman JD, Donnally C, Trimmer CK, Cadeddu JA (2010) Durable oncologic outcomes after radiofrequency ablation: experience from treating 243 small renal masses over 7.5 years. Cancer 116:3135–3142CrossRefPubMedGoogle Scholar
  4. 4.
    Ma Y, Bedir S, Cadeddu JA, Gahan JC (2014) Long-term outcomes in healthy adults after radiofrequency ablation of T1a renal tumours. BJU Int 113:51–55CrossRefPubMedGoogle Scholar
  5. 5.
    Wehrenberg-Klee E, Clark TWI, Malkowicz SB, Soulen MC, Wein AJ, Mondschein JI, Van Arsdalen K, Guzzo TJ, Stavropoulos SW (2012) Impact on renal function of percutaneous thermal ablation of renal masses in patients with preexisting chronic kidney disease. J Vasc Interv Radiol 23:41–45CrossRefPubMedGoogle Scholar
  6. 6.
    Raman JD, Raj GV, Lucas SM, Williams SK, Lauer EM, Ahrar K, Matin SF, Leveillee RJ, Cadeddu JA (2010) Renal functional outcomes for tumours in a solitary kidney managed by ablative or extirpative techniques. BJU Int 105:496–500CrossRefPubMedGoogle Scholar
  7. 7.
    Atwell TD, Carter RE, Schmit GD, Carr CM, Boorjian SA, Curry TB, Thompson RH, Kurup AN, Weisbrod AJ, Chow GK, Leibovich BC, Callstrom MR, Patterson DE (2012) Complications following 573 percutaneous renal radiofrequency and cryoablation procedures. J Vasc Interv Radiol 23:48–54CrossRefPubMedGoogle Scholar
  8. 8.
    Kunkle DA, Egleston BL, Uzzo RG (2008) Excise, ablate or observe: the small renal mass dilemma—a meta-analysis and review. J Urol 179:1227–1233CrossRefPubMedGoogle Scholar
  9. 9.
    Gervais DA, McGovern FJ, Arellano RS, McDougal WS, Mueller PR (2005) Radiofrequency ablation of renal cell carcinoma: part 1, indications, results, and role in patient management over a 6-year period and ablation of 100 tumors. AJR Am J Roentgenol 185:64–71CrossRefPubMedGoogle Scholar
  10. 10.
    Zagoria RJ, Pettus JA, Rogers M, Werle DM, Childs D, Leyendecker JR (2011) Long-term outcomes after percutaneous radiofrequency ablation for renal cell carcinoma. Urology 77:1393–1397CrossRefPubMedGoogle Scholar
  11. 11.
    Van Poppel H, Becker F, Cadeddu JA, Gill IS, Janetschek G, Jewett MAS, Laguna MP, Marberger M, Montorsi F, Polascik TJ, Ukimura O, Zhu G (2011) Treatment of localised renal cell carcinoma. Eur Urol 60:662–672CrossRefPubMedGoogle Scholar
  12. 12.
    Ferakis N, Bouropoulos C, Granitsas T, Mylona S, Poulias I (2010) Long-term results after computed-tomography-guided percutaneous radiofrequency ablation for small renal tumors. J Endourol 24:1909–1913CrossRefPubMedGoogle Scholar
  13. 13.
    Psutka SP, Feldman AS, McDougal WS, McGovern FJ, Mueller P, Gervais DA (2013) Long-term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma. Eur Urol 63:486–492CrossRefPubMedGoogle Scholar
  14. 14.
    Wingo MS, Leveillee RJ (2008) Central and deep renal tumors can be effectively ablated: radiofrequency ablation outcomes with fiberoptic peripheral temperature monitoring. J Endourol 22:1261–1267CrossRefPubMedGoogle Scholar
  15. 15.
    Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibanes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M (2009) The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 250:187–196CrossRefPubMedGoogle Scholar
  16. 16.
    Sabharwal R, Vladica P (2006) Renal tumors: technical success and early clinical experience with radiofrequency ablation of 18 tumors. Cardiovasc Intervent Radiol 29:202–209CrossRefPubMedGoogle Scholar
  17. 17.
    Goldberg SN, Gazelle GS, Compton CC, Mueller PR, Tanabe KK (2000) Treatment of intrahepatic malignancy with radiofrequency ablation: radiologic-pathologic correlation. Cancer 88:2452–2463CrossRefPubMedGoogle Scholar
  18. 18.
    Kutikov A, Uzzo RG (2009) The R.E.N.A.L. Nephrometry Score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol 182:844–853CrossRefPubMedGoogle Scholar
  19. 19.
    Stern JM, Svatek R, Park S, Hermann M, Lotan Y, Sagalowsky AI, Cadeddu JA (2007) Intermediate comparison of partial nephrectomy and radiofrequency ablation for clinical T1a renal tumours. BJU Int 100:287–290CrossRefPubMedGoogle Scholar
  20. 20.
    Levinson AW, Su L-M, Agarwal D, Sroka M, Jarrett TW, Kavoussi LR, Solomon SB (2008) Long-term oncological and overall outcomes of percutaneous radio frequency ablation in high risk surgical patients with a solitary small renal mass. J Urol 180:499–504CrossRefPubMedGoogle Scholar
  21. 21.
    Joniau S, Tailly T, Goeman L, Blyweert W, Gontero P, Joyce A (2010) Kidney radiofrequency ablation for small renal tumors: oncologic efficacy. J Endourol 24:721–728CrossRefPubMedGoogle Scholar
  22. 22.
    Campbell SC, Novick AC, Belldegrun A, Blute ML, Chow GK, Derweesh IH, Faraday MM, Kaouk JH, Leveillee RJ, Matin SF, Russo P, Uzzo RG, Practice Guidelines Committee of the American Urological A (2009) Guideline for management of the clinical T1 renal mass. J Urol 182:1271–1279CrossRefPubMedGoogle Scholar
  23. 23.
    Best SL, Park SK, Youssef RF, Olweny EO, Tan YK, Trimmer C, Cadeddu JA (2012) Long-term outcomes of renal tumor radio frequency ablation stratified by tumor diameter: size matters. J Urol 187(6):2284CrossRefGoogle Scholar
  24. 24.
    Gervais DA, Arellano RS, McGovern FJ, McDougal WS, Mueller PR (2005) Radiofrequency ablation of renal cell carcinoma: part 2, lessons learned with ablation of 100 tumors. AJR Am J Roentgenol 185:72–80CrossRefPubMedGoogle Scholar
  25. 25.
    Hiraoka K, Kawauchi A, Nakamura T, Soh J, Mikami K, Miki T (2009) Radiofrequency ablation for renal tumors: our experience. Int J Urol 16:869–873CrossRefPubMedGoogle Scholar
  26. 26.
    Johnson JR, Williams G, Pazdur R (2003) End points and United States food and drug administration approval of oncology drugs. J Clin Oncol 21:1404–1411CrossRefPubMedGoogle Scholar
  27. 27.
    Weight CJ, Larson BT, Gao T, Campbell SC, Lane BR, Kaouk JH, Gill IS, Klein EA, Fergany AF (2010) Elective partial nephrectomy in patients with clinical T1b renal tumors is associated with improved overall survival. Urology 76:631–637CrossRefPubMedGoogle Scholar
  28. 28.
    Zini L, Perrotte P, Capitanio U, Jeldres C, Shariat SF, Antebi E, Saad F, Patard J-J, Montorsi F, Karakiewicz PI (2009) Radical versus partial nephrectomy: effect on overall and noncancer mortality. Cancer 115:1465–1471CrossRefPubMedGoogle Scholar
  29. 29.
    Huang WC, Elkin EB, Levey AS, Jang TL, Russo P (2009) Partial nephrectomy versus radical nephrectomy in patients with small renal tumors-is there a difference in mortality and cardiovascular outcomes? J Urol 181:55–61CrossRefPubMedGoogle Scholar
  30. 30.
    Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40:373–383CrossRefPubMedGoogle Scholar
  31. 31.
    Johnson DB, Solomon SB, Su LM, Matsumoto ED, Kavoussi LR, Nakada SY, Moon TD, Shingleton WB, Cadeddu JA (2004) Defining the complications of cryoablation and radio frequency ablation of small renal tumors: a multi-institutional review. J Urol 172:874–877CrossRefPubMedGoogle Scholar
  32. 32.
    Poon RT, Ng KK, Lam CM, Ai V, Yuen J, Fan ST, Wong J (2004) Learning curve for radiofrequency ablation of liver tumors: prospective analysis of initial 100 patients in a tertiary institution. Ann Surg 239:441–449CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Weizer AZ, Raj GV, O’Connell M, Robertson CN, Nelson RC, Polascik TJ (2005) Complications after percutaneous radiofrequency ablation of renal tumors. Urology 66:1176–1180CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2016

Authors and Affiliations

  • Michael Z. Su
    • 1
  • Fatima Memon
    • 3
  • Howard M. Lau
    • 2
  • Andrew J. Brooks
    • 2
  • Manish I. Patel
    • 2
  • Henry H. Woo
    • 4
  • Simon V. Bariol
    • 2
  • Philip Vladica
    • 3
  1. 1.Department of SurgeryUniversity of Sydney, Westmead HospitalWestmeadAustralia
  2. 2.Department of UrologyWestmead HospitalSydneyAustralia
  3. 3.Department of RadiologyWestmead HospitalSydneyAustralia
  4. 4.Sydney Medical SchoolUniversity of SydneyWahroongaAustralia

Personalised recommendations